3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pain
5
Colorectal Neoplasms
5
Neoplasms
4
Breast Neoplasms
4
Stomatitis
3
Neoplasm Metastasis
3
Adenoma
3
Urologic Neoplasms
2
Stomach Neoplasms
2
Mucositis
2
Insulin Resistance
2
Head and Neck Neoplasms
2
Vulvodynia
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
Melanoma
1
MRSA Colonization
1
Interventions
Fluorouracil
267
Oxaliplatin
266
Capecitabine
224
Leucovorin
209
Irinotecan
151
Radiotherapy
131
Bevacizumab
112
Cetuximab
81
Folfox protocol
48
Surgical Procedures, Operative
44
Radiation
41
Drug Therapy
41
Neoadjuvant Therapy
40
Chemoradiotherapy
33
Chemotherapy, Adjuvant
32
Panitumumab
27
XELOX
25
Magnetic Resonance Spectroscopy
22
Radiotherapy, Intensity-Modulated
21
Floxuridine
17
Biopsy
16
Nivolumab
15
Gemcitabine
15
Early Intervention, Educational
15
pembrolizumab
14
Laparoscopy
14
IFL protocol
14
Celecoxib
14
trifluridine tipiracil drug combination
13
Gene Expression Profiling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rectal Neoplasms
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled